# RNAZ (Transcode Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Transcode Therapeutics, Inc. reported $44.75M in total assets and a net loss of $145.4M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/RNAZ
- Markdown: https://convexityos.com/fundamentals/RNAZ.md
- SEC CIK: 0001829635
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:12 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001829635&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$150.3M | Operating profit |
| Net Income | FY 2025 | -$145.4M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$12.68 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$19.52M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $4.64M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $13.42M | $9.71M | $12.26M | $10.23M | $2.75M | $284K |
| Total Operating Expenses | $27.98M | $15.66M | $19.42M | $18.63M | $6.15M | $727K |
| **Operating Income** | -$27.98M | -$15.66M | -$19.42M | -$18.63M | -$6.15M | -$727K |
| **EBITDA** | -$27.97M | -$15.57M | -$19.30M | -$18.54M | -$6.11M | -$727K |
| Interest Income | $79K | $684 | $5.3K | $20K | $664 | $136 |
| Interest Expense | $6.6K | $27K | $56K | $32K | $95K | $395K |
| Income Before Tax | -$34.44M | -$16.75M | -- | -- | -- | -- |
| Income Tax Expense | $226K | $0 | $0 | $0 | $53K | $0 |
| **Net Income** | -$34.66M | -$16.75M | -$18.55M | -$17.56M | -$6.84M | -$2.34M |
| Basic EPS | -$52.59 | -$1,336.63 | -$88,050,733.97 | -$1,083,621,591,147.68 | -$12,471,109,020,068.87 | -$7,852,179,753,376.69 |
| **Diluted EPS** | -$52.59 | -$1,336.63 | -$88,050,733.97 | -$1,083,621,591,147.68 | -$12,471,109,020,068.87 | -$7,852,179,753,376.69 |
| Basic Shares Outstanding | 689.7K | 12.6K | 0 | 0 | 0 | 0 |
| Diluted Shares Outstanding | 689.7K | 12.6K | 0 | 0 | 0 | 0 |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $3.55M | $3.69M | $5.11M | $5.48M | $3.16M | $2.57M | $2.22M | $3.64M |
| Total Operating Expenses | $109.7M | $6.79M | $17.76M | $16.03M | $4.56M | $4.22M | $3.17M | $5.09M |
| **Operating Income** | -$109.7M | -$6.79M | -$17.76M | -$16.03M | -$4.56M | -$4.22M | -$3.17M | -$5.09M |
| **EBITDA** | -$109.7M | -$6.77M | -$17.73M | -$16.04M | -$4.56M | -$4.21M | -$3.16M | -$5.08M |
| Interest Income | $43K | $52K | $92K | $79K | $147 | $148 | $146 | $159 |
| Interest Expense | $7.0K | -- | -- | $542 | $6.0K | $0 | $114 | $1.8K |
| Income Before Tax | -$107.7M | -$6.75M | -$17.55M | -$13.22M | -$4.86M | -$4.28M | -$12.09M | -- |
| Income Tax Expense | -- | -- | -- | $226K | $0 | $0 | $0 | $0 |
| **Net Income** | -$107.4M | -$6.75M | -$17.79M | -$13.44M | -$4.86M | -$4.28M | -$12.09M | -$5.92M |
| Basic EPS | -$9.36 | -$7.17 | -$21.28 | -- | -$5.82 | -$5.13 | -$70.16 | -- |
| **Diluted EPS** | -$9.36 | -$7.17 | -$21.28 | -- | -$5.82 | -$5.13 | -$70.16 | -- |
| Basic Shares Outstanding | 11.5M | 957.2K | 917.0K | -- | 833.7K | 833.7K | 172.3K | -- |
| Diluted Shares Outstanding | 11.5M | 957.2K | 917.0K | -- | 833.7K | 833.7K | 172.3K | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $17.81M | $5.81M | $2.77M | $4.97M | $20.83M | $828K |
| **Cash & Short-Term Investments** | $17.81M | $5.81M | $2.77M | $4.97M | $20.83M | $828K |
| **Total Current Assets** | $21.98M | $7.09M | $4.46M | $7.38M | $22.73M | $831K |
| Property, Plant & Equipment, Net | $371K | $52K | $121K | $209K | $206K | -- |
| Goodwill | $25.74M | -- | -- | -- | -- | -- |
| Intangible Assets | $114.3M | -- | -- | -- | -- | -- |
| **Total Non-Current Assets** | $140.4M | $201K | $714K | $209K | $206K | $224K |
| **Total Assets** | $162.4M | $7.29M | $5.17M | $7.59M | $22.94M | $1.06M |
| Deferred Revenue (Current) | $0 | $25K | $27K | $0 | $31K | $0 |
| **Total Current Liabilities** | $3.49M | $2.77M | $3.49M | $4.35M | $2.53M | $405K |
| **Total Non-Current Liabilities** | $7.02M | $6.54M | $38K | $0 | $0 | $4.06M |
| **Total Liabilities** | $10.52M | $9.31M | $3.53M | $4.35M | $2.53M | $4.46M |
| **Total Debt (incl. Leases)** | -- | $38K | $451K | -- | -- | -- |
| Common Stock | $92 | $4 | $2 | $2 | $1.3K | $464 |
| Retained Earnings | -$97.86M | -$63.20M | -$46.42M | -$27.87M | -$10.31M | -$3.46M |
| **Total Stockholders' Equity** | $10.34M | -$2.02M | $1.64M | $3.24M | $20.40M | -$3.41M |
| Total Equity | $10.34M | -$2.02M | $1.64M | $3.24M | $20.40M | -$3.41M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $4.64M | $8.38M | $12.84M | $17.81M | $2.84M | $7.37M | $11.57M | $5.81M |
| **Cash & Short-Term Investments** | $4.64M | $8.38M | $12.84M | $17.81M | $2.84M | $7.37M | $11.57M | $5.81M |
| **Total Current Assets** | $6.70M | $10.64M | $16.75M | $21.98M | $4.75M | $8.24M | $13.04M | $7.09M |
| Property, Plant & Equipment, Net | $9.3K | $323K | $347K | $371K | $20K | $25K | $38K | $52K |
| Goodwill | $25.74M | $25.74M | $25.74M | $25.74M | -- | -- | -- | -- |
| Intangible Assets | $12.30M | $114.3M | $114.3M | $114.3M | -- | -- | -- | -- |
| **Total Non-Current Assets** | $38.05M | $140.4M | $140.4M | $140.4M | $476K | $25K | $150K | $201K |
| **Total Assets** | $44.75M | $151.0M | $157.2M | $162.4M | $5.23M | $8.27M | $13.19M | $7.29M |
| Deferred Revenue (Current) | $0 | $64K | $85K | $0 | $0 | $0 | $0 | $25K |
| **Total Current Liabilities** | $6.98M | $5.40M | $5.38M | $3.49M | $2.97M | $1.56M | $2.51M | $2.77M |
| **Total Non-Current Liabilities** | $5.63M | $7.25M | $7.27M | $7.02M | $833K | $554K | $392K | $6.54M |
| **Total Liabilities** | $12.61M | $12.65M | $12.64M | $10.52M | $3.80M | $2.12M | $2.90M | $9.31M |
| **Total Debt (incl. Leases)** | -- | -- | -- | -- | -- | -- | -- | $38K |
| Common Stock | $1.7K | $101 | $92 | $92 | $84 | $84 | $2.3K | $4 |
| Retained Earnings | -$229.8M | -$122.4M | -$115.6M | -$97.86M | -$84.42M | -$79.56M | -$75.29M | -$63.20M |
| **Total Stockholders' Equity** | $32.14M | -$27.69M | $1.25M | $10.34M | $1.43M | $6.15M | $10.29M | -$2.02M |
| Total Equity | $32.14M | -$27.69M | $1.25M | $10.34M | $1.43M | $6.15M | $10.29M | -$2.02M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$34.66M | -$16.75M | -$18.55M | -$17.56M | -$6.84M | -$2.34M |
| Depreciation & Amortization | $13K | $91K | $123K | $99K | $42K | $0 |
| Stock-Based Compensation | $485K | $1.70M | $1.04M | $395K | $186K | $45K |
| **Operating Cash Flow** | -$19.52M | -$13.34M | -$18.07M | -$15.76M | -$5.27M | -$493K |
| Capital Expenditure | -$6.7K | -$22K | -$36K | -$101K | -$255K | -- |
| **Free Cash Flow** | -$19.52M | -$13.36M | -$18.11M | -$15.86M | -$5.52M | -- |
| **Investing Cash Flow** | -$4.4K | -$22K | -$36K | -$101K | -$252K | -- |
| Common Stock Issued | $8.85M | $16.40M | $15.91M | $1.30M | -- | -- |
| **Financing Cash Flow** | $31.52M | $16.40M | $15.91M | $6.0K | $25.52M | $1.12M |
| **Net Change in Cash** | $12.00M | $3.04M | -$2.20M | -$15.86M | $20.00M | $624K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$107.4M | -$6.75M | -$17.79M | -$13.44M | -$4.86M | -$4.28M | -$12.09M | -$5.92M |
| Depreciation & Amortization | $22K | $24K | $24K | -$18K | $4.8K | $13K | $13K | $10K |
| Stock-Based Compensation | $315K | -- | -- | $62K | $134K | $132K | $158K | $169K |
| **Operating Cash Flow** | -$7.66M | -$5.40M | -$4.98M | -$8.14M | -$4.08M | -$4.19M | -$3.10M | -$3.15M |
| Capital Expenditure | -- | -- | -- | -- | -- | -- | -- | -$500 |
| **Free Cash Flow** | -- | -- | -- | -- | -- | -- | -- | -$3.15M |
| **Investing Cash Flow** | -- | -- | -- | -- | -- | -- | -- | -$500 |
| Common Stock Issued | -- | -- | -- | $1 | $0 | $0 | $8.85M | $7.08M |
| **Financing Cash Flow** | -- | -- | -- | $23.12M | -$456K | $0 | $8.85M | $7.08M |
| **Net Change in Cash** | -$3.75M | -$4.45M | -$4.98M | $14.98M | -$4.54M | -$4.19M | $5.76M | $3.94M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -335.4% | -- | -1130.3% | -542.0% | -33.5% | -- |
| Return on Assets (ROA) | -21.3% | -229.7% | -358.7% | -231.5% | -29.8% | -222.1% |
| Current Ratio | 6.29x | 2.56x | 1.28x | 1.70x | 8.97x | 2.05x |
| Quick Ratio | 5.10x | 2.10x | 0.79x | 1.14x | 8.22x | 2.05x |
| Debt to Equity | -- | -- | 0.27x | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -452.3% | -- | -3225.2% | -335.4% | -1902.8% | -400.1% | -247.9% | -- |
| Return on Assets (ROA) | -324.8% | -28.4% | -25.7% | -21.3% | -519.1% | -297.6% | -193.4% | -229.7% |
| Current Ratio | 0.96x | 1.97x | 3.11x | 6.29x | 1.60x | 5.27x | 5.20x | 2.56x |
| Quick Ratio | 0.66x | 1.55x | 2.39x | 5.10x | 0.96x | 4.71x | 4.61x | 2.10x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
